FDA approves new styles of Allergan's breast implants; Medtronic launches new stent graft;

@FierceMedDev: Glooko merges tech data to avoid activity-triggered hypoglycemic events. More | Follow @FierceMedDev

@VarunSaxena2: Philips, Duke to collaborate on infant temperature monitoring using InnerSense probe. Article | Follow @VarunSaxena2

@EmilyWFierce: $BSX ordered to pay $26.7M in one of first federal trials over vaginal mesh devices. Story | Follow @EmilyWFierce

> After receiving both FDA approval and a CE mark for the the Endurant IIs abdominal aortic aneurysm (AAA) stent graft, Medtronic ($MDT) launched the minimally invasive product in the U.S. and Europe. Story

> The FDA approved two new styles of Allergan's ($AGN) silicone-filled breast implants for use in breast reconstruction, augmentation and revision surgeries. Release

> AstraZeneca ($AZN) is running an InnoCentive challenge, with a $25,000 prize, to find improvements to predective cardiac in vitro assays, providing an insight into the company's research interests in diagnostics and the potential for somebody to make some cash-money. More

Biotech News

@FierceBiotech: IPOs: $FGEN comes up big while $NDRM limps out of the gate. Story | Follow @FierceBiotech

@JohnCFierce: Puma drug neratinib flunks PFS, ORR endpoints. Article | Follow @JohnCFierce

@DamianFierce: $GERN rides again as $JNJ partners up on imetelstat for up to $900M. Release | Follow @DamianFierce

> Alexion co-founder will retire in January. Chutes & Ladders

> Boehringer taps WellPoint's outcomes data to develop new a-fib drugs. More

> J&J bets up to $935M that Geron's drug can shake a checkered past. Article

Pharma News

@FiercePharma: Top-read special report: The top 10 #pharma companies by 2013 revenue. Report | Follow @FiercePharma

@EricPFierce: ICYMI: Cadilia gets slapped with #FDA warning for not following up on complaints about stinking APIs. More | Follow @EricPFierce

@CarlyHFierce: Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal. Story | Follow @CarlyHFierce

> Another Pfizer run at AZ? Unlikely, Reuters' sources say. But keep an eye on Actavis. More

> EMA director Rasi sidelined by complaint from colleague who wanted his job. Article

> New biologics plant for Bristol-Myers promises 400 jobs for Ireland. News

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.